These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4681210)

  • 1. Effects of 2,5-dimethoxy-4-methylamphetamine on the behavior of rats in competition for food.
    Uyeno ET
    Int Pharmacopsychiatry; 1972; 7(1-4):244-8. PubMed ID: 4681210
    [No Abstract]   [Full Text] [Related]  

  • 2. Stereoselective effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) on schedule-controlled behavior.
    Harris RA; Snell D; Loh HH
    Pharmacol Biochem Behav; 1977 Oct; 7(4):307-10. PubMed ID: 928488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,5-Dimethoxy-4-methylamphetamine (DOM)- a central component of its cardiovascular effects in rats; involvement of serotonin.
    Friedman E; Lambert GA; Buchweitz E
    Eur J Pharmacol; 1978 May; 49(2):157-61. PubMed ID: 26578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents.
    Glennon RA; Rosecrans JA; Young R
    Med Res Rev; 1983; 3(3):289-340. PubMed ID: 6350763
    [No Abstract]   [Full Text] [Related]  

  • 5. MDA and DOM: substituted amphetamines that do not produce amphetamine-like discriminative stimuli in the rat.
    Shannon HE
    Psychopharmacology (Berl); 1980; 67(3):311-2. PubMed ID: 6770411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM) and d-amphetamine on operant responding in control and 6-hydroxydopamine-treated rats.
    Commissaris R; Lyness WH; Cordon JJ; Moore KE; Rech RH
    Pharmacol Biochem Behav; 1980 Nov; 13(5):621-6. PubMed ID: 7443731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines.
    Glennon RA; Young R; Jacyno JM; Slusher M; Rosecrans JA
    Eur J Pharmacol; 1983 Jan; 86(3-4):453-9. PubMed ID: 6572591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological aspects of hallucinogenic drugs.
    Logan WJ
    Adv Neurol; 1975; 13():47-78. PubMed ID: 814800
    [No Abstract]   [Full Text] [Related]  

  • 9. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats.
    Nichols DE; Hoffman AJ; Oberlender RA; Riggs RM
    J Med Chem; 1986 Feb; 29(2):302-4. PubMed ID: 3950910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A characteristic effect of hallucinogens on investigatory responding in rats.
    Geyer MA; Light RK; Rose GJ; Petersen LR; Horwitt DD; Adams LM; Hawkins RL
    Psychopharmacology (Berl); 1979 Sep; 65(1):35-40. PubMed ID: 116288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of d-lysergic acid diethylamide, d-2-bromolysergic acid diethylamide, dl-2,5-dimethoxy-4-methylamphetamine and d-amphetamine on classical conditioning of the rabbit nictitating membrane response.
    Harvey JA; Gormezano I; Cool VA
    J Pharmacol Exp Ther; 1982 May; 221(2):289-94. PubMed ID: 6122729
    [No Abstract]   [Full Text] [Related]  

  • 13. Naloxone alters the effects of LSD, DOM and quipazine on operant behavior of rats.
    Mokler DJ; Commissaris RL; Henck JW; Rech RH
    Pharmacol Biochem Behav; 1984 Sep; 21(3):333-7. PubMed ID: 6593750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR studies on psychotomimetic phenylalkylamines.
    Gupta SP; Handa A; Bindal MC; Singh P
    Arzneimittelforschung; 1983; 33(8):1089-90. PubMed ID: 6685483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of delta9-tetrahydrocannabinol & 2, 5-dimethoxy-4-methylamphetamine on rat sexual dominance behavior.
    Uyeno ET
    Proc West Pharmacol Soc; 1976; 19():369-72. PubMed ID: 996008
    [No Abstract]   [Full Text] [Related]  

  • 16. Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.
    Muschamp JW; Regina MJ; Hull EM; Winter JC; Rabin RA
    Brain Res; 2004 Oct; 1023(1):134-40. PubMed ID: 15364028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists.
    Mokler DJ; Commissaris RL; Warner MR; Rech RH
    J Pharmacol Exp Ther; 1983 Dec; 227(3):557-62. PubMed ID: 6655557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural correlation between apomorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens.
    Nichols DE
    J Theor Biol; 1976 Jun; 59(1):167-77. PubMed ID: 7711
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of 2,5-dimethoxy-4-methylamphetamine (DOM) on operant behavior: interactions with other neuroactive agents.
    Commissaris RL; Semeyn DR; Moore KE; Rech RH
    Commun Psychopharmacol; 1980; 4(5):393-404. PubMed ID: 6120791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.